# Case Report: Re-irradiation of out-of-field recurrence of malignant phyllodes tumors of the breast after adjuvant radiotherapy

## TL;DR

A case report explores the use of re-irradiation for a rare malignant breast tumor recurrence after initial radiotherapy.

## Contribution

The report provides insights into re-irradiation safety and effectiveness for recurrent malignant phyllodes tumors.

## Key findings

- Re-irradiation (45–60 Gy/25 fractions) was feasible and effective in preventing local recurrence in a patient with recurrent malignant phyllodes tumor.
- Adjuvant radiotherapy significantly reduced recurrence rates in this case.
- Careful selection of re-irradiation candidates may improve outcomes in recurrent malignant phyllodes tumors.

## Abstract

Phyllodes tumor of the breast (PTB) is a rare fibroepithelial neoplasm, classified as benign, borderline, and malignant. They typically present as solitary, painless, firm masses with potential rapid enlargement, and 20% exceed 10 cm, often indicating malignancy. Local recurrence frequently occurs within two years postoperatively. While the survival benefit of adjuvant radiotherapy remains controversial, it significantly reduces recurrence rates. We report a 27×14 cm malignant PTB and evaluate optimal radiotherapy strategies and re-irradiation safety in recurrent cases.

A 55-year-old female presented with a rapidly enlarging left breast mass, initially detected seven years prior, measuring 50×40 cm on physical examination. The patient underwent complete surgical excision, with a postoperative pathological mass measuring 27×14 cm, followed by adjuvant radiotherapy (50 Gy/25 fractions). One month after radiation, a 15×15 cm axillary recurrence was resected (10×8 cm specimen). Two months later, a 10×8 cm infraclavicular recurrence was excised (6×5 cm specimen). Subsequently, six cycles of epirubicin–cyclophosphamide chemotherapy and re-irradiation (45–60 Gy/25 fractions) were administered. At present, there is no evidence of local recurrence.

This case highlights the potential role of adjuvant RT in reducing recurrence and the feasibility of carefully selected re-irradiation for recurrent MPTs. Prospective studies are needed to define optimal target volume of radiotherapy, dose fractionation, and the safety of re-irradiation.